Eric Strom

Dr. Eric Strom

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2005 in Cancer
Verified
Journal Article
Open access
PDF file
ACAllen M. Chen
Allen M. Chen
FMFunda Meric-Bernstam
Funda Meric-Bernstam
KHKelly K. Hunt
Kelly K. Hunt
HTHoward D. Thames
Howard D. Thames
EOElesyia D. Outlaw
Elesyia D. Outlaw
TBThomas Buchholz
Thomas Buchholz
BACKGROUND: The appropriate selection criteria for breast‐conserving therapy (BCT) after neoadjuvant chemotherapy are poorly defined. The purpose of the current report was to develop a prognostic index to help refine selection criteria and to serve as a general framework for clinical decision‐making for patients treated by this multimodality approach.METHODS: From a group of 340 patients treated with BCT after neoadjuvant chemotherapy, the authors previously determined 4 statistically significant predictors of ipsilateral breast tumor recurrence (IBTR) and locoregional recurrence (LRR): clinical N2 or N3 disease, residual pathologic tumor size > than 2 cm, a multifocal pattern of residual disease, and lymphovascular space invasion in the specimen. The M. D. Anderson Prognostic Index (MDAPI) was developed by assigning scores of 0 (favorable) or 1 (unfavorable) for each of these 4 variables and using the total to give an overall MDAPI score of 0–4.RESULTS: The MDAPI stratified the 340 patients into 3 subsets with statistically different levels of risk for IBTR and LRR after neoadjuvant chemotherapy and BCT. Actuarial 5‐year IBTR‐free survival rates were 97%, 88%, and 82% for patients in the low (MDAPI overall score 0 or 1, n = 276), intermediate (MDAPI score 2, n = 43), and high (MDAPI score 3 or 4, n = 12) risk groups, respectively (P < 0.001). Corresponding actuarial 5‐year LRR‐free survival rates were 94%, 83%, and 58%, respectively (P < 0.001).CONCLUSIONS: Patients with an MDAPI score of 0 or 1, which made up 81% of the study population, had very low rates of IBTR and LRR. The MDAPI enabled the identification of a small group (4%) of patients who are at high risk for IBTR and LRR and who may benefit from alternative locoregional treatment strategies. Cancer 2005. © 2005 American Cancer Society.

10 November 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BMBeryl McCormick
Beryl McCormick
KWKathryn A. Winter
Kathryn A. Winter
WWWendy Woodward
Wendy Woodward
HKHenry M. Kuerer
Henry M. Kuerer
NSNour Sneige
Nour Sneige
JWJulia R. White
Julia R. White
PURPOSE: To our knowledge, NRG/RTOG 9804 is the only randomized trial to assess the impact of whole breast irradiation (radiation therapy [RT]) versus observation (OBS) in women with good-risk ductal carcinoma in situ (DCIS), following lumpectomy. Long-term results focusing on ipsilateral breast recurrence (IBR), the primary outcome, are presented here. PATIENTS AND METHODS: Eligible patients underwent lumpectomy for DCIS that was mammogram detected, size ≤ 2.5 cm, final margins ≥ 3 mm, and low or intermediate nuclear grade. Consented patients were randomly assigned to RT or OBS. Tamoxifen use was optional. Cumulative incidence was used to estimate IBR, log-rank test and Gray's test to compare treatments, and Fine-Gray regression for hazard ratios (HRs). RESULTS: A total of six hundred thirty-six women were randomly assigned from 1999 to 2006. Median age was 58 years and mean pathologic DCIS size was 0.60 cm. Intention to use tamoxifen was balanced between arms (69%); however, actual receipt of tamoxifen varied, 58% RT versus 66% OBS ( P = .05). At 13.9 years' median follow-up, the 15-year cumulative incidence of IBR was 7.1% (95% CI, 4.0 to 11.5) with RT versus 15.1% (95% CI, 10.8 to 20.2) OBS ( P = .0007; HR = 0.36; 95% CI, 0.20 to 0.66); and for invasive LR was 5.4% (95% CI, 2.7 to 9.5) RT versus 9.5% (95% CI, 6.0 to 13.9) OBS ( P = .027; HR = 0.44; 95% CI, 0.21 to 0.91). On multivariable analysis, only RT (HR = 0.34; 95% CI, 0.19 to 0.64; P = .0007) and tamoxifen use (HR = 0.45; 95% CI, 0.25 to 0.78; P = .0047) were associated with reduced IBR. CONCLUSION: RT significantly reduced all and invasive IBR for good-risk DCIS with durable results at 15 years. These results are not an absolute indication for RT but rather should inform shared patient-physician treatment decisions about ipsilateral breast risk reduction in the long term following lumpectomy.

1 December 2005 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
ESEric Strom
Eric Strom
WWWendy A. Woodward
Wendy A. Woodward
AKAngela Katz
Angela Katz
TBThomas A. Buchholz
Thomas A. Buchholz
GPGeorge H. Perkins
George H. Perkins
MMMarsha D. McNeese
Marsha D. McNeese

26 February 2004 in Cancer
Verified
Journal Article
Closed access
PDF file
TBThomas Buchholz
Thomas Buchholz
MWMichael M. Weil
Michael M. Weil
CACheryl L. Ashorn
Cheryl L. Ashorn
ESEric Strom
Eric Strom
ASAlice Sigurdson
Alice Sigurdson
MSMichael Story
Michael Story

11 January 2013 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
HSHeath Devin Skinner
Heath Devin Skinner
ESEric Strom
Eric Strom
SMSabin B Motwani
Sabin B Motwani
WWWendy A Woodward
Wendy A Woodward
MGMarjorie C Green
Marjorie C Green
TBThomas Buchholz
Thomas Buchholz
Background: Radiation is a standard component of treatment for patients with locoregional recurrence (LRR) of breast cancer following mastectomy. The current study reports the results of a 10% radiation dose escalation in these patients. Methods: 159 patients treated at MD Anderson Cancer Center between 1994-2006 with isolated LRR after mastectomy alone were reviewed. Patients in the standard treatment group (65 pts, 40.9%) were treated to 50 Gy comprehensively plus a boost of 10 Gy. The dose escalated group (94 pts, 59.1%) was treated to 54 Gy comprehensively and a minimum 12 Gy boost. Median dose in the standard dose and dose escalated group was 60 Gy (±1 Gy, 95% CI) and 66 Gy (±0.5 Gy, 95% CI) respectively. Median follow up for living patients was 94 months from time of recurrence. Results: The actuarial five year locoregional control (LRC) rate was 77% for the entire study population. The five year overall survival and disease-free survival was 55% and 41%, respectively. On multivariate analysis, initial tumor size (p = 0.03), time to initial LRR (p = 0.03), absence of gross tumor at the time of radiation (p = 0.001) and Her2 status (p = 0.03) were associated with improved LRC. Five year LRC rates were similar in patients with a complete response to chemotherapy without surgery and patients with a complete surgical excision (77% vs 83%, p = NS), compared to a 63% LRC rate in patients with gross disease at the time of radiation (p = 0.024). LRC rates were 80% in the standard dose group and 75% in the dose escalated group (p = NS). Conclusions: While LRR following mastectomy is potentially curable, distant metastasis and local control rates remain suboptimal. Radiation dose escalation did not appear to improve LRC. Given significant local failure rates, these patients are good candidates for additional strategies to improve their outcomes.

20 January 2004 in Cancer
Verified
Journal Article
Open access
PDF file
Tim PawlikTim Pawlik
Tim Pawlik
APAllison Perry
Allison Perry
ESEric Strom
Eric Strom
GBGildy V. Babiera
Gildy V. Babiera
TBThomas A. Buchholz
Thomas A. Buchholz
HKHenry M. Kuerer
Henry M. Kuerer
BACKGROUND Balloon catheter–based accelerated partial breast irradiation (APBI) is an alternative to whole‐breast external‐beam irradiation during breast‐conserving therapy (BCT) for breast carcinoma, but it is limited by the size of the segmental mastectomy cavity. There are scant data on the average or optimal volume of resection (VR) in BCT. The objective of the current study was to evaluate the percentage of patients who would be eligible for balloon catheter–based APBI based on the selection criteria of the American Society of Breast Surgeons and the surgical VR. METHODS The authors reviewed the medical records of 443 patients with ductal carcinoma in situ (DCIS) or invasive carcinoma treated with BCT. Patient treatment and pathologic data were analyzed to assess VR and eligibility for APBI. RESULTS BCT was performed for 178 patients with DCIS and 267 patients with invasive breast carcinoma. The majority of invasive carcinomas (63.3%) were infiltrating ductal carcinomas. The median overall lumpectomy volume was 67.61 cm3, with no significant difference between DCIS and invasive carcinoma (P > 0.05). Although the majority (62.9–82.0%) of patients met the individual selection criteria for APBI, only 27.4% of the cohort was found to be eligible for any type of APBI when the selection criteria were considered together. Based on VR, only approximately one‐half of the patients initially eligible for APBI would be candidates for immediate balloon catheter–based APBI using the 70 cm3 balloon device (13.3%). However, with the new, larger 125 cm3 balloon device, approximately three‐fourths of patients initially eligible for APBI would be eligible for balloon catheter–based APBI at the time of the initial surgical procedure (20.7%). Although not evaluated in the current study, shrinkage of the lumpectomy cavity with time may increase the number of patients eligible based strictly on VR criteria. Patients with a very large VR (≥ 125 cm3) were more likely to have invasive carcinoma (P = 0.02; hazard ratio [HR], 7.4) and tumors ≥ 5 cm on final pathology (P < 0.01; HR, 22.0). CONCLUSIONS Approximately one‐fifth to one‐fourth of patients presenting for BCT may be eligible for balloon catheter–based APBI according to accepted national guidelines and VR. VR must be considered when selecting patients for balloon catheter–based APBI, because a minority of patients will have a lumpectomy cavity that exceeds the size limit of the current balloon device. Cancer 2004. © 2003 American Cancer Society.